Benzydamine in Sore Throat Pain Relief (BePaiR Study)

Angelini Pharma

Status and phase

Completed

Phase 4

Conditions

Acute Sore Throat

Treatments

Drug: Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)

Drug: 0.3% benzydamine hydrochloride spray oromucosal solution

Study type

Interventional

Funder types

Industry

Other

Identifiers

NCT04941976

030(Z)WO19176

2019-003257-29 (EudraCT Number)

Details and patient eligibility

About

The aim of this study is to generate new clinical data about the speed of relief provided by a single application of Benzydamine hydrochloride 0,3% oromucosal spray vs Benzydamine hydrochloride 3 mg lozenges mint flavour.

Full description

The efficacy and safety of benzydamine local-applied, in the treatment of various throat inflammatory and painful conditions, had been widely demonstrated.

The aim of this study is to generate new clinical data about the speed of relief provided by a single application of Benzydamine hydrochloride 0,3% oromucosal spray or Benzydamine hydrochloride 3 mg lozenges mint flavour.

The study will be conducted at 15 sites located among Poland, Hungary and Russia (5 sites for each country).

356 patients affected by acute sore throat will be enrolled in out-patient clinics or out-patient departments of city hospitals.

Enrollment

356 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Adult male and female patients (aged 18 - 75 years, limits included) with recent onset (≤3 days) of sore throat and a diagnosis of tonsillopharyngitis confirmed by:
1. Presence of at least one symptom of URTI in the previous 24 h on the URTI questionnaire;
2. Sore throat pain intensity score ≥ 60 mm on Sore Throat Pain Intensity Scale (STPIS);
3. A score ≥ 5 on Tonsillo-Pharingytis Assessment (TPA);
Women of childbearing potential or with no menses for a period < 12 months must have a negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the signature of the informed consent up to the Visit 2, using an appropriate birth control method such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone-releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered:
- Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.
Patients legally capable of giving their consent to participate in the study (including personal data processing) and available to sign and date the written informed consent.

Exclusion criteria

Known hypersensitivity to benzydamine or its excipients;
Phenylketonuria;
Clinically significant abnormalities at physical examination and vital signs;
Intolerance to acetylsalicylic acid or other NSAIDS;
History or diagnosis of asthma;
Any concomitant disease that compromise breathing (i.e. bronchopneumonia);
Mouth breathing due to nasal congestion which causes throat drying;
Severe coughing which causes throat discomfort;
Purulent plaques on the tonsils;
Any inhaled therapy in the previous week before the first drug administration;
Use of antibiotics for an acute disease in the 7 days before randomisation (chronic antibiotic use, such as for acne, is acceptable); any sustained release analgesic within 24 hours of administration of study medication; any medications for cold and flu (i.e., decongestants, antihistamines, expectorants, antitussives), immediate release analgesic or antipyretic within 4 hours of administration of study medication;
Use of any lozenge, mouthwash, spray or menthol-containing products within 2 hours of administration of study medication;
Women during pregnancy or lactation period;
Subject involved in the conduct of the study (e.g. Investigator or his/her deputy, first grade relatives, pharmacist, assistant or other personnel, etc);
Participation to a clinical trial within 3 months prior to the inclusion in the study.